Skip to main content
Fig. 3 | Cancer Cell International

Fig. 3

From: Cost-effectiveness and accuracy of cervical cancer screening with a high-risk HPV genotyping assay vs a nongenotyping assay in China: an observational cohort study

Fig. 3

Screening procedures for Cervista® cotesting and PCR-RDB cotesting in Arm 1 and Arm 2/Arm 3. a Cervista® cotesting in Arm 1 primarily screens women with both cytology and Cervista® HR-HPV assays in Arm 1 and then refers those with cytology ASCUS and HR-HPV positive/cytology LSIL or worse for colposcopy; b PCR-RDB cotesting with 16/18 genotyping in Arm 1 primarily screens women with both cytology and PCR-RDB HPV genotyping assays in Arm 1 and then refers those with cytology ASC-US and PCR-RDB HR-HPV positive/PCR-RDB HPV16 or HPV18 positive/cytology LSIL or worse for colposcopy; c Cervista® cotesting in Arm 2/Arm 3, primarily screens women with both cytology and Cervista® HR-HPV assays in Arm 2/Arm 3 and then refers those with cytology ASCUS and HR-HPV positive/cytology LSIL or worse for colposcopy; d PCR-RDB cotesting with 16/18 genotyping in Arm 2/Arm 3, primarily screens women with both cytology and PCR-RDB HPV genotyping assays in Arm 2/Arm 3 and then refers those with cytology ASCUS and PCR-RDB HR-HPV positive/PCR-RDB HPV16 or HPV18 positive/cytology LSIL or worse for colposcopy. HR-HPV, high-risk human papillomavirus; NILM, negative for intraepithelial lesion or malignancy; ASCUS, atypical squamous cells of undetermined significance; ≥ LSIL, low-grade squamous intraepithelial lesion or worse, including atypical squamous cells without excluding high-grade lesions and atypical glandular cells

Back to article page

Cancer Cell International

ISSN: 1475-2867

Contact us